Navigation Links
Interim Safety Analysis Supports Continuation of Allos Therapeutics' Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-cell Lymphoma
Date:12/27/2007

WESTMINSTER, Colo., Dec. 27 /PRNewswire-FirstCall/ -- Allos Therapeutics, Inc. (Nasdaq: ALTH) today announced that an independent Data Monitoring Committee (DMC) has completed the pre-specified 65-patient safety review of data from the Company's pivotal Phase 2 PROPEL trial of PDX (pralatrexate) in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL), and has recommended that the trial continue per the protocol. This interim assessment was based upon an evaluation of patients enrolled in the study who completed at least one cycle of treatment with PDX. The Company currently expects to complete patient enrollment in the PROPEL study in the second quarter of 2008.

"The DMC recommendation represents another important milestone in the development of a potential new treatment option for patients with relapsed or refractory peripheral T-cell lymphoma, a patient population for which there are currently no approved agents," said Pablo J. Cagnoni, M.D., Senior Vice President and Chief Medical Officer of Allos. "We remain pleased with the progress of the PROPEL trial and look forward to continuing to drive our PDX product development and commercialization plans in 2008."

PROPEL (Pralatrexate in Patients with Relapsed Or Refractory PEripheral T-cell Lymphoma) is a pivotal Phase 2, international, multi-center, open-label, single-arm study that will seek to enroll a minimum of 100 evaluable patients with relapsed or refractory PTCL who have progressed after at least one prior treatment. Patients receive 30 mg/m2 of PDX once every week for six weeks followed by one week of rest per cycle of treatment. The primary efficacy endpoint of the study is objective response rate (complete and partial response). Secondary efficacy
'/>"/>

SOURCE Allos Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
2. Interim Response and Safety Analyses Support Continuation of Allos Therapeutics Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-Cell Lymphoma
3. Immtech Announces Interim Analysis in Phase III African Sleeping Sickness Trial
4. Interim Safety Data Favorable for Vicals Phase 2 Trial of DNA Vaccine Against CMV
5. Interim Phase 2 Data for Exelixis XL880 Show Anti-Tumor Activity in Papillary Renal Cell Cancer
6. Leading Physicians Present Interim Results from Multi-Center Studies of VNUS ClosureFAST Catheter at VEITHsymposium
7. Grantees of the Avon Foundation Breast Cancer Prevention Research Initiative Gather in Houston to Report Interim Findings
8. Novavax Announces Favorable Interim Results from Human Clinical Trial for Its Pandemic Influenza Vaccine Program
9. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
10. Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
11. Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 2014  Commonwealth Cornerstone Group (CCG) today announced the completion ... Tuesday to help fund the expansion and consolidation of healthcare ... Sharon . PHN is the largest ... . It is the largest employer in Sharon,s ... on staff. Currently, PHN Sharon offers scattered services ...
(Date:12/24/2014)...  The International Trade Commission (ITC) issued its final decision ... In a notice issued on December 23, the ITC ruled ... its humidifier was invalid. BMC President, James ... very excited with the ITC,s decision in this case. This ... since the very beginning on the key patents in the ...
(Date:12/24/2014)... YORK and LONDON , ... global orthopedic industry are expected to grow at an ... in terms of value and volume. Hip, knee and ... developed world while in emerging economies they have a ... rates are challenging the use of composites. Non-metallic orthopedic ...
Breaking Medicine Technology:Commonwealth Cornerstone Group Announces $8 Million in Tax Credits to Expand and Consolidate Healthcare Services in Sharon 2Commonwealth Cornerstone Group Announces $8 Million in Tax Credits to Expand and Consolidate Healthcare Services in Sharon 3ITC Final Decision Goes Against ResMed (RMD) Monumental Win for 3B/BMC 2Use of Composites in Orthopedic Industry to Reach $596 Million by 2020 2Use of Composites in Orthopedic Industry to Reach $596 Million by 2020 3
... STAAR Surgical Company (NASDAQ: STAA ), a ... products, today reported financial results for the first quarter ... 8% to $14.8 million over the first quarter of ... and ICL) sales.  The Company achieved its first quarter ...
... 3, 2011 Jazz Pharmaceuticals, Inc. (Nasdaq: JAZZ ) ... Total revenues for the quarter ended March ... the first quarter of 2010.  Total revenues included net product ... for the first quarter of 2011 was $21.8 million, or ...
Cached Medicine Technology:STAAR Surgical Reports First Quarterly Profit from Continuing Operations Since 2000 2STAAR Surgical Reports First Quarterly Profit from Continuing Operations Since 2000 3STAAR Surgical Reports First Quarterly Profit from Continuing Operations Since 2000 4STAAR Surgical Reports First Quarterly Profit from Continuing Operations Since 2000 5STAAR Surgical Reports First Quarterly Profit from Continuing Operations Since 2000 6STAAR Surgical Reports First Quarterly Profit from Continuing Operations Since 2000 7STAAR Surgical Reports First Quarterly Profit from Continuing Operations Since 2000 8STAAR Surgical Reports First Quarterly Profit from Continuing Operations Since 2000 9STAAR Surgical Reports First Quarterly Profit from Continuing Operations Since 2000 10STAAR Surgical Reports First Quarterly Profit from Continuing Operations Since 2000 11Jazz Pharmaceuticals Announces First Quarter 2011 Financial Results 2Jazz Pharmaceuticals Announces First Quarter 2011 Financial Results 3Jazz Pharmaceuticals Announces First Quarter 2011 Financial Results 4Jazz Pharmaceuticals Announces First Quarter 2011 Financial Results 5Jazz Pharmaceuticals Announces First Quarter 2011 Financial Results 6Jazz Pharmaceuticals Announces First Quarter 2011 Financial Results 7
(Date:12/24/2014)... 2014 Dr. Vu Ho, a Dallas ... his practice and med-spa with the addition of new ... of cosmetic treatments and services. , “Silk Peel is ... says Dr. Ho. “As a result it can address ... sun spots, discolorations or blemishes.” , Similar to microdermabrasion, ...
(Date:12/24/2014)... TX (PRWEB) December 25, 2014 The ... to 2023” focuses on the current treatment landscape, unmet ... cancer market. Stivarga is a drug which is used ... drug is orally administered and is also prescribed to ... drug which is FDA approved is a multi-kinase inhibitor ...
(Date:12/24/2014)... (HealthDay News) -- The holidays can be a challenge for ... certain foods and drinks. "This is the season in ... of migraine," Dr. David Dodick, chair of the American Migraine ... "It,s important to think through food and beverage choices, to ... Dodick, a professor of neurology at the Mayo Clinic in ...
(Date:12/24/2014)... 24, 2014 (HealthDay News) -- Researchers say they have ... develop into eggs and sperm. While this had ... the first time that these types of cells -- ... using human stem cells, according to the team at ... of primordial germ cells is one of the earliest ...
(Date:12/24/2014)... 2014 Gluten, a protein found predominately ... have an intolerance to gluten, causing side effects that ... headaches, joint pain and fatigue. For this reason, Diet ... that deliver safe and fast weight loss while teaching ... gluten allergy reaction. These gluten free diet plans combine ...
Breaking Medicine News(10 mins):Health News:Dr. Vu Ho Expands Facial Plastic Surgery Practice to Include New Skin Care Treatment 2Health News:Stivarga Colorectal Cancer Treatment Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:Stivarga Colorectal Cancer Treatment Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Expert Offers Tips for Preventing Holiday Migraines 2Health News:Diet Doc Adds Gluten Free Diet Plans to Their Stable of Specialized Weight Loss Programs 2Health News:Diet Doc Adds Gluten Free Diet Plans to Their Stable of Specialized Weight Loss Programs 3
... ... and Ethan Nadelmann, PhD, JD, is Keynote Speaker on the Failed War on Drugs ... Las Vegas, NV (PRWEB) September ... founder of the Drug Policy Alliance advocating for drug reform in the United States as ...
... U.S. reports unusually high flu activity, most of it swine ... officials said Friday that additional trials of the H1N1 swine ... a strong immune response in healthy adults. , The findings ... that found that a single dose of the vaccine creates ...
... , WINSTON-SALEM, N.C., Sept. 11 Sales of ... three years after the FDA approved the drug an estimated three ... advertising and lobbying for government mandates. A recent marketing study ... professor of marketing at Wake Forest University, and several colleagues conducted ...
... , TERRE HAUTE, Ind., Sept. 11 Indiana State University,s ... environmental health sciences professors using the campus as her classroom. , ... year at the school, is teaching the course titled "Communicable and Chronic ... to learn about various types of pathogens - the biological agents that ...
... , , , WASHINGTON, ... Civil Rights and Elections (AMT), a coalition of major national Islamic organizations, ... health care reform. , , DATE: Tuesday, September 15, ... Hill, Washington, D. C. , , TIME: 10 AM-1 ...
... , SEATTLE, Sept. 11 The following ... the synthesis blog, winner of the 2008 Weblog award for ... , It,s true that the devil is in the details, ... about the outcome you,re trying to create, then whatever you,re doing, however ...
Cached Medicine News:Health News:Healthcare Legal Issues Take the Stage at PAINWeek 2009 2Health News:Healthcare Legal Issues Take the Stage at PAINWeek 2009 3Health News:Swine Flu Trials Continue to Point to 1-Dose Vaccine 2Health News:Swine Flu Trials Continue to Point to 1-Dose Vaccine 3Health News:HPV Vaccine Study Shows Why Few Women Getting Shots 2Health News:Professor Uses H1N1 as a Teaching Tool 2Health News:Professor Uses H1N1 as a Teaching Tool 3Health News:Muslim Coalition to Host D.C. Hearing on Health Care Reform 2
... Tissue Sectioning System has maintained the reputation ... Researchers from around the globe have relied ... fresh and fresh fixed tissue sectioning needs ... the Vibratome Automatic Tissue Sectioning Systems, the ...
Replacement bulb for Vibratome light system....
Injector blades come ten to an injector and allow for the easy replacement of Vibratome cutting blades....
Vibratome Specimen Adhesive is a special formulation developed by a major adhesive manufacturer for applications such as tissue mounting. The advantage of this adhesive is that it has a strong holdi...
Medicine Products: